Opzelura - direct healthcare professional communication (DHPC)

ruxolitinib phosphate

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Direct healthcare professional communication (DHPC) : Opzelura 15 mg/g cream (ruxolitinib phosphate): Important information regarding presence of particles in Opzelura cream

Key facts

• Medicine name:
  Opzelura
• Active substance:
  ruxolitinib phosphate
• Therapeutic area (MeSH):
  Vitiligo
• DHPC type:
  Quality defect
• Human ATC codes:
  D11AH
• Dissemination date:
  24/04/2025